Although the clinical relevance on the aforementioned cardiovascular threat factor alterations by tirzepatide will be assessed in the planned cardiovascular end result study SURPASS-CVOT ( "variety":"scientific-trial","attrs": "text":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Evaluation indicated that ti